Efficacy of quercetin against polymicrobial biofilm on catheters

Every year, the catheter-associated urinary tract infections (CAUTIs) experience a very significant number of increases. Urinary tract infections constitute about 30% of nosocomial infections, and about 75% of all bacterial species show biofilm production, which provides survival benefits to offering protection from environmental stresses and causing decreased susceptibility to antimicrobial agents. Until now the discovery of catheter antibiofilm compounds is still minimal, therefore the development of a new candidate antibiofilm for polymicrobial biofilms in catheters is a challenge that must be overcome in preventing catheter-associated urinary tract infections (CAUTIs). This study aimed to determine the effectiveness of quercetin in inhibited and decreased polymicrobial biofilm formation in catheters: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans. The test for inhibition of the degradation of polymicrobial biofilms on catheters was determined using the microtiter broth method. The use of quercetin on polymicrobial biofilms was analyzed by calculating the minimum biofilm inhibitory concentration (MBIC50) and the minimum value of biofilm eradication (MBEC50). The relationship of quercetin work against S. aureus, P. aeruginosa, E. coli, and C. albicans polymicrobial biofilms was tested by using scanning electron microscopy (SEM). Quercetin 1% gave 50% inhibitory activity to the formation of polymicrobial catheter biofilms at 24 h and 48 h at 53.55±0.01 and 50.38 ± 0.01 in comparison to control (nystatin and chloramphenicol). The results also proved evidence of quercetin activity that can degrade polymicrobial catheter biofilms by 46.48%±0.01 and damage the polymicrobial biofilm matrix extracellular polymeric substance (EPS) on the catheter. Quercetin seems to inhibitory activity against the formation of polymicrobial biofilms in catheters and is very potential to be developed as a candidate for new antibiofilm drugs against urinary tract infections.